13 news items
Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies
VIR
13 May 24
broadly neutralizing monoclonal antibody targeting hepatitis B virus (HBV) and BRII-835 (elebsiran), an investigational HBV-targeting small
Deep Dive Into Vir Biotechnology Stock: Analyst Perspectives (6 Ratings)
VIR
7 May 24
1
0
0
The 12-month price targets assessed
HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $110 Price Target
VIR
7 May 24
HC Wainwright & Co. analyst Patrick Trucchio reiterates Vir Biotechnology (NASDAQ:VIR) with a Buy and maintains $110 price target.
JP Morgan Maintains Neutral on Vir Biotechnology, Raises Price Target to $12
VIR
3 May 24
JP Morgan analyst Eric Joseph maintains Vir Biotechnology (NASDAQ:VIR) with a Neutral and raises the price target from $10 to $12.
Needham Reiterates Buy on Vir Biotechnology, Maintains $15 Price Target
VIR
3 May 24
Needham analyst Joseph Stringer reiterates Vir Biotechnology (NASDAQ:VIR) with a Buy and maintains $15 price target.
dbsfw
VIR
11 Apr 24
system by exploiting critical observations of natural immune processes. Its current clinical development pipeline consists of product candidates targeting
nu9igxjtozlmngq8zgsebqgrp78hb42fa7ikxvvhwggd1yy4g25
ANTX
VBIV
VIR
22 Mar 24
to assess and enhance HBV patients' intrinsic immunity, targeting therapies to those most likely to respond, while sparing others from poorly
4rujzv8 aqtzw5ve62fex1g8l07tl0bx1l5
VIR
15 Mar 24
Analysts have set 12-month price targets for Vir Biotechnology, revealing an average target of $64.8, a high estimate
elbmq4hoz4amqluo4z9xp1ybr1qn bkgs5r7o
VIR
15 Mar 24
HC Wainwright & Co. analyst Patrick Trucchio reiterates Vir Biotechnology (NASDAQ:VIR) with a Buy and maintains $110 price target.
7kr bej4knmo3gdphhaq30xu00j2fh4j6mc3q
VIR
5 Mar 24
virus-targeting small interfering ribonucleic acid (siRNA) that Vir believes has the potential to stimulate an immune response and have direct antiviral
7k9pfoo21eg oeursj6medlusoflzigf6r0q4ax7ll0kjp
AAOI
ACCO
AKRO
23 Feb 24
a Neutral rating on the stock and raised its price target from $12 to $13.5.
ATN International, Inc
04urnwg9e7u2w4boxwfn19lk5ptqyqxklfzgx1cygc05how02pzd8b
VIR
23 Feb 24
processes. Its current clinical development pipeline consists of product candidates targeting hepatitis delta and hepatitis B viruses and human
4m7i19faj bln87rjavacauyu016lumdj7ufk8c9h5v9f
VIR
22 Feb 24
neuraminidase-targeting mAb against both influenza A and B viruses.
VIR-8190, an investigational mAb
- Prev
- 1
- Next